Sana Biotechnology Inc vs Sotera Health Company Common Stock — how do they compare? Sana Biotechnology Inc trades at $2.34 (market cap $697.51M), while Sotera Health Company Common Stock trades at $17.75 (market cap $5.06B). The key difference: Sotera Health Company Common Stock is far larger — about 7.3× Sana Biotechnology Inc's market cap, and Sotera Health Company Common Stock is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 24 Days and Sotera Health Company Common Stock for 0 Days on average.
| SANA | SHC | |
|---|---|---|
Market Cap | $697.51M | $5.06B |
Volume | 2,763,583 | 2,279,715 |
Sector | Health | Health |
52-Week High | $5.92 | $19.57 |
52-Week Low | $2.33 | $13.13 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $610.76M | $6.97B |
Signals from Pluang's Aura AI — not financial advice
Sana Biotechnology (SANA) trades at $2.41, down 8.02% in the last session, reflecting a bearish technical trend despite bullish oscillators. The company is pre-revenue with significant losses, reporting a net income of -$244.17 million in 2025 and negative cash flow, while maintaining a price-to-book ratio of 4.51. Recent news highlights active participation in investor conferences and a positive analyst consensus.
The outlook is speculative, with high risk due to no current revenue and substantial cash burn, but potential upside exists if clinical developments succeed, supported by an analyst consensus price target of $8.50. Key risks include funding needs, clinical trial outcomes, and competitive pressures in biotechnology.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Sotera Health Company is a US provider of sterilization and lab testing services for the healthcare industry, operating through its Sterigenics, Nordion, and Nelson Labs businesses.
Read more on SHC →